Alpha 2.0
Login Register
» Articles » PMID: 31449289

Addressing the Rising Prices of Disease-Modifying Therapies for Multiple Sclerosis

Overview
Journal JAMA Neurol
Publisher American Medical Association
Date 2019 Aug 27
PMID 31449289
Citations 7
Authors
Daniel M Hartung
Dennis Bourdette
Affiliations
Soon will be listed here.
Citing Articles

Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis.

Allen-Philbey K, De Trane S, MacDougall A, Adams A, Bianchi L, Campion T Ther Adv Neurol Disord. 2023; 16:17562864231200627.

PMID: 37954917 PMC: 10638874. DOI: 10.1177/17562864231200627.

Association Between Pharmacy Benefit Restrictions and Disease-Modifying Therapy Use in the Medicare Part D Program.

Hartung D, Johnston K, McGregor J, Bourdette D Neurol Clin Pract. 2022; 12(1):36-42.

PMID: 36157618 PMC: 9491506. DOI: 10.1212/CPJ.0000000000001118.

Characteristics of Prescription Drug Use Among Individuals With Multiple Sclerosis in the US Medicare Population.

Hartung D, Johnston K, McGregor J, Bourdette D Int J MS Care. 2022; 24(2):90-97.

PMID: 35462869 PMC: 9017658. DOI: 10.7224/1537-2073.2021-062.

The Neuroimmunology of Multiple Sclerosis: Fictions and Facts.

Pachner A Front Neurol. 2022; 12:796378.

PMID: 35197914 PMC: 8858985. DOI: 10.3389/fneur.2021.796378.

Closing the Part D Coverage Gap and Out-of-Pocket Costs for Multiple Sclerosis Drugs.

Hartung D, Johnston K, Bourdette D, Chen R, Tseng C Neurol Clin Pract. 2021; 11(4):298-303.

PMID: 34484929 PMC: 8382442. DOI: 10.1212/CPJ.0000000000000929.